Nidufexor
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 24, 2016 (NCT02913105)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Bile acid receptorAGONIST
NR1H4 agonist
- Bile acid receptor FXRAGONIST
Bile acid receptor FXR agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(=O)O)cc2)c2c1-c1cc(Cl)ccc1OC2- Mol. weight
- 487.94 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297626 ↗
Also known as
- lmb763
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03804879 | Phase 2 | Dec 17, 2018 | Novartis |
| NCT02913105 | Phase 2 | Oct 24, 2016 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1